公开(公告)号：EP3377516A1

公开(公告)日：2018-09-26

申请号：EP16867262.4

申请日：2016-11-18

申请人： Memorial Sloan Kettering Cancer Center

发明人： SCHEINBERG, David

IPC分类号： C07K7/08 ,  A61K39/00 ,  C07K14/47

CPC分类号： A61K39/001153 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/55505 ,  A61K2039/55522 ,  A61K2039/892 ,  A61P35/00 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/82

摘要： This invention provides methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, by administering a combination of at least one WT1 peptide, or cytotoxic T cells (CTLs) against a WT1-expressing cancer, and at least one checkpoint inhibitor. The at least one WT1 peptide can be administered to the subject by administering one or more agents to the subject resulting in delivery of one or more WT1 peptides and induction of an immune response against the WT1-expressing cancer. Examples of these WT1 delivery agents include: (i) an isolated WT1 peptide, (ii) a nucleic acid encoding the at least one WT1 peptide, and (iii) an immune cell comprising or presenting the at least one WT1 peptide or nucleic acid encoding the at least one WT1 peptide.

公开(公告)号：EP3280738A1

公开(公告)日：2018-02-14

申请号：EP16777432.2

申请日：2016-04-08

申请人： Nantomics, LLC

发明人： BENZ, Stephen Charles ,  NGUYEN, Andrew ,  VASKE, Charles Joseph ,  SANBORN, John Zachary

IPC分类号： C07K16/30 ,  C07K14/725 ,  C07K19/00 ,  C12N5/0783 ,  C12N15/62 ,  G01N33/574 ,  A61K39/395 ,  A61K47/48 ,  A61K49/16

CPC分类号： C07K16/30 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/80 ,  A61K2039/812 ,  A61K2039/892 ,  C07K14/4702 ,  C07K16/22 ,  C07K2317/34 ,  C07K2319/55 ,  C07K2319/60 ,  C12N5/0693 ,  G01N33/57407

摘要： Certain universal neoepitopes and cancer specific neoepitopes and methods therefor are presented that may be used in immunotherapy and cancer diagnosis. Preferred therapeutic and diagnostic compositions include antibodies or fragments thereof that bind to neoepitopes on cancer cells.

公开(公告)号：EP3350337A1

公开(公告)日：2018-07-25

申请号：EP16847136.5

申请日：2016-09-13

申请人： Advaxis, Inc. ,  The Trustees of the University of Pennsylvania

发明人： WALLECHA, Anu ,  PATERSON, Yvonne

IPC分类号： C12P21/00 ,  C12N15/74 ,  C07K14/005 ,  C07K14/195 ,  A61K38/16

CPC分类号： C12N15/74 ,  A61K35/74 ,  A61K39/0011 ,  A61K39/12 ,  A61K2039/585 ,  A61K2039/6068 ,  A61K2039/6075 ,  A61K2039/892 ,  A61P35/00 ,  C07K14/005 ,  C07K14/025 ,  C07K14/195 ,  C07K19/00 ,  C07K2319/06 ,  C07K2319/55 ,  C12N1/20 ,  C12N5/00 ,  C12N2330/50 ,  C12N2511/00 ,  C12N2710/20022 ,  C12N2710/20033 ,  C12N2710/20034 ,  C12N2710/20043 ,  C12N2710/20051 ,  C12N2740/16234 ,  C12N2800/101 ,  C12P21/00

摘要： The present invention discloses a process for manufacturing a formulation comprising a drug substance, said drug substance comprising a recombinant Listeria comprising a human papilloma virus (HPV) antigen fused to a Listeriolysin O (LLO) protein fragment. The invention further discloses methods of using treating, protecting against, and inducing an immune response against cervical cancer comprising administration of the recombinant Listeria strain. The present invention also provides methods for inducing an anti-E7 CTL response in a human subject and treating HPV-mediated diseases, disorders, and symptoms, comprising administration of the recombinant Listeria strain.